Ind-Swift Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ind-Swift Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 98% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 97% of Healthcare companies in India.
- Shareholder Slice Ratio: Share count rose 47% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 96% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-34Over the last 3 years, every ₹100 of reported profit came with ₹-34 of operating cash.
Lower than 96% of Healthcare companies in India.
Self-Funding Ratio
-1.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 97% of Healthcare companies in India.
Cash Locked Ratio
₹22For every ₹100 of sales, ₹22 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹59 tied up three years earlier.
Less money tied up than 53% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 48%
Sales fell 48% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-48% / -8%In 3 years sales changed by -48% while total assets changed by -8%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-12.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 98% of Healthcare companies in India.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 94% of Healthcare companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 53% of Healthcare companies in India.
Tangible Net Worth Ratio
98%Of every ₹100 of net worth, ₹98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 57% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Ind-Swift Laboratories Limited owes ₹0.17 for every ₹1 it owns. Net profit fell 83% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
51.6Investors pay ₹51.6 for every ₹1 of Ind-Swift Laboratories Limited's yearly profit, higher than 72% of Healthcare companies in India.
P/B ratio
2.17The share price is 2.17 times Ind-Swift Laboratories Limited's book value per share, lower than 86% of Healthcare companies in India.
Market cap
₹3,003 CrThe total market value of all of Ind-Swift Laboratories Limited's shares at today's price (share price × number of shares), smaller than 58% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,384 CrWhat Ind-Swift Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹159.15Net worth divided by the number of shares. The share price of ₹345.35 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
4.0%Ind-Swift Laboratories Limited earned 4.0% on its shareholders' money over the last year, lower than 85% of Healthcare companies in India.
Owes vs Owns
0.17×Ind-Swift Laboratories Limited owes ₹0.17 for every ₹1 it owns (low), lower than 86% of Healthcare companies in India.
Dividend yield
NoneInd-Swift Laboratories Limited does not currently pay a dividend.
Revenue growth
+11%Revenue rose 11% in the year to Mar 2026, and shrank 20% a year on average over 3 years.
Profit growth
-83%Net profit fell 83% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Profit margin
6.9%Ind-Swift Laboratories Limited keeps ₹7 of every ₹100 of revenue as net profit.
Cash quality
-1.6×Cash from Ind-Swift Laboratories Limited's business was -1.6× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
Not coveredInd-Swift Laboratories Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net cashInd-Swift Laboratories Limited held ₹424 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Ind-Swift Laboratories Limited's P/E ratio?
Investors pay ₹51.6 for every ₹1 of Ind-Swift Laboratories Limited's yearly profit, higher than 72% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ind-Swift Laboratories Limited: ₹3,003 Cr ÷ ₹1,384 Cr (31 Mar 2026) = 2.2.
What is Ind-Swift Laboratories Limited's return on equity?
Ind-Swift Laboratories Limited earned 4.0% on its shareholders' money over the last year, lower than 85% of Healthcare companies in India.
How much does Ind-Swift Laboratories Limited owe compared with what it owns?
Ind-Swift Laboratories Limited owes ₹0.17 for every ₹1 it owns (low), lower than 86% of Healthcare companies in India.
Does Ind-Swift Laboratories Limited pay a dividend?
No. Ind-Swift Laboratories Limited does not currently pay a dividend.
Is Ind-Swift Laboratories Limited's revenue growing?
Revenue rose 11% in the year to Mar 2026, and shrank 20% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.